Eric Schmidt

Insider Reports History

Entity
Individual
Location
C/O Allogene Therapeutics, Inc., 210 East Grand Avenue, South San Francisco, CA
Signature
/s/ Jack Anders, as Attorney-in-fact for Eric Schmidt
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Eric Schmidt:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Allogene Therapeutics, Inc. Chief Financial Officer Common Stock 1.15M $3.66M $3.17 Mar 22, 2023 Indirect
Allogene Therapeutics, Inc. Chief Financial Officer Common Stock 862K $2.74M $3.17 Mar 22, 2023 Direct
Revolution Medicines, Inc. Director Common Stock 21.3K $574K $27.00 Jun 8, 2023 Direct
Allogene Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 433K Mar 22, 2023 Direct
RELMADA THERAPEUTICS, INC. Director Stock Option (right to buy) 150K May 25, 2023 Direct
Revolution Medicines, Inc. Director Stock Option (Right to Buy) 18.4K Jun 8, 2023 Direct

Insider Reports Filed by Eric Schmidt

Symbol Company Period Transactions Value $ Form Type Date Filed Role
RVMD Revolution Medicines, Inc. Jun 8, 2023 2 $0 4 Jun 12, 2023 Director
RLMD RELMADA THERAPEUTICS, INC. May 25, 2023 1 $0 4 May 30, 2023 Director
ALLO Allogene Therapeutics, Inc. Mar 22, 2023 2 $0 4 Mar 24, 2023 Chief Financial Officer
ALLO Allogene Therapeutics, Inc. Mar 14, 2023 1 -$196K 4 Mar 16, 2023 Chief Financial Officer
RLMD RELMADA THERAPEUTICS, INC. Dec 16, 2022 1 $0 4 Dec 20, 2022 Director
RVMD Revolution Medicines, Inc. Jun 16, 2022 2 $0 4 Jun 17, 2022 Director
ALLO Allogene Therapeutics, Inc. Mar 23, 2022 2 $0 4 Mar 25, 2022 Chief Financial Officer
ALLO Allogene Therapeutics, Inc. Mar 15, 2022 1 -$87.6K 4 Mar 17, 2022 Chief Financial Officer
RLMD RELMADA THERAPEUTICS, INC. Dec 17, 2021 1 $0 4 May 26, 2022 Director
RLMD RELMADA THERAPEUTICS, INC. Dec 17, 2021 1 $0 4 Dec 21, 2021 Director
RVMD Revolution Medicines, Inc. Jun 22, 2021 2 $0 4 Jun 24, 2021 Director
ALLO Allogene Therapeutics, Inc. May 24, 2021 2 $271K 4 May 26, 2021 Chief Financial Officer